<DOC>
	<DOCNO>NCT00387777</DOCNO>
	<brief_summary>The purpose study determine whether Transtec ( R ) PRO 70 µg/h new buprenorphine patch formulation lead plasma level buprenorphine multiple dose application .</brief_summary>
	<brief_title>Multiple Dose Trial Comparing Plasma Levels Two Different Analgesic Transdermal Patch Formulations</brief_title>
	<detailed_description>Main : To demonstrate bioequivalence new buprenorphine transdermal patch T2rev formulation contain 13 mg buprenorphine ( Test ) compare Transtec ( R ) PRO 70 µg/h patch transdermal patch contain 40 mg buprenorphine reference multiple patch application . Pharmacokinetic target parameter AUCss , Tau Css , max . Further : To assess safety , tolerability , skin tolerability adhesiveness patch application . To evaluate follow Pharmacokinetic parameter : Css , min , Css , ave , PTF , Swing , tss , max , t1/2 , z</detailed_description>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Male Caucasian subject , age 18 55 year BMI 18 30 kg/m2 inclusive , lover limit body weight 50 kg Subjects must good health determine medical history , physical examination , 12lead electrocardiogram , vital sign , clinical laboratory parameter Subjects give write informed consent participate within trial Resting pulse rate &lt; = 45 &gt; = 100 beats/min Resting blood pressure : systolic blood pressure &lt; = 90 &gt; = 160 mmHg , diastolic blood pressure &lt; = 40 &gt; = 100 mmHg History presence orthostatic hypotension Positive test HIV type 1/2 antibody , HBs antigen , HBc antibody , HCV antibodies Participation another clinical trial last 30 day start trial ( i.e. , first administration IMP ) Positive drug abuse screening Diseases condition know interfere absorption , distribution , metabolism excretion drug Marked repolarisation abnormality ( e.g. , suspicious definite congenital long QT syndrome QT/QTc &gt; 500msec prolonged QTc , i.e. &gt; 450msec ) comedication know influence cardiac repolarisation substantially Bronchial asthma Definite suspect history drug allergy hypersensitivity Subjects receive prescribed nonprescribed systemic topical medication like analgesic , NSAIDs ( except standard dose NSAID week treatment headache ) , hypnotic , sedative , narcotic , neuroleptic medication may lower seizure threshold , MAOinhibitors , serotoninreuptakeinhibitors , tricyclic antidepressant , centrally act substance substance know interact drug metabolize enzyme ( e.g. , inhibitor inducer CYP3A4 CYP2D6 ) four week prior start trial ( i.e , first administration IMP ) . Each case decide upon individually investigator consultation sponsor Evidence alcohol drug abuse Not able abstain consumption : Caffeine contain beverage food ( tea , coffee , cola , chocolate , etc . ) Quinine contain beverage food ( bitter lemon , tonic water ) Grapefruit juice ( sweet , sour ) Poppy seed contain beverage food Blood loss ( &gt; 100 mL ) due e.g. , blood donation within 3 month start trial ( i.e. , first administration IMP ) History seizures risk ( i.e . head trauma , epilepsy family anamnesis , unclear loss consciousness ) Known suspect able comply trial protocol Not able communicate meaningfully investigator staff Smoking &gt; 10 cigarettes/day equivalent . Trial specific exclusion criterion : Subjects able abstain strenuous exercise whole course trial Abnormality ( e. g. scar , tattoo ) unhealthy skin application site accord examination investigator Existing chronic skin disease history skin disease application site within last 4 week Presence one contraindication detailed current Summary Product Characteristics ( SmPC ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>Transdermal patch</keyword>
	<keyword>multidose</keyword>
	<keyword>Centrally act analgesic</keyword>
	<keyword>Plasma level</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>